Comparison of the effectiveness of pirfenidone and nintedanib in patients with advanced stage idiopathic pulmonary fibrosis
Keywords:
Idiopathic Pulmonary Fibrosis, Advanced stage, Nintedanib, Pirfenidone, Mortality, Antifibrotic therapyAbstract
Background and aim: Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with high mortality, especially in advanced stages, defined as forced vital capacity (FVC) ≤50% and/or diffusing capacity of the lungs for carbon monoxide (DLCO) ≤30% of predicted values. While antifibrotic therapies, such as nintedanib and pirfenidone, are effective in mild to moderate IPF, their efficacy in advanced-stage IPF remains unclear due to the exclusion of these patients from major clinical trials. This study aimed to compare the effectiveness of nintedanib and pirfenidone on mortality and to identify predictors of mortality in patients with advanced-stage IPF.
Methods: This retrospective cohort study included 198 advanced-stage IPF patients treated with nintedanib (n=91) or pirfenidone (n=107) between 2017 and 2023. Demographic, clinical, and radiological data were collected. Mortality predictors were analyzed using multivariate Cox regression, and survival outcomes were compared using adjusted Kaplan-Meier curves.
Results: Independent predictors of mortality were found to be six-minute walk distance (HR=0.99, 95% CI: 0.996–0.999, p=0.049), pulmonary fibrosis score ≥150 (HR=1.86, 95% CI: 1.07–3.22, p=0.026), and heart failure (HR=2.24, 95% CI: 1.18–4.26, p=0.014). After adjusting for these factors, no significant differences in mortality were observed between the nintedanib and pirfenidone groups.
Conclusions: Nintedanib and pirfenidone showed comparable effectiveness in reducing mortality among advanced-stage IPF patients. Future clinical trials should include advanced-stage patients to better evaluate treatment efficacy in this population.
References
1. Raghu G, Collard HR, Egan JJ, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44-e68. doi: 10.1164/rccm.201807-1255ST
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82. doi: 10.1056/NEJMoa1402584
3. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47:243-53. doi: 10.1183/13993003.00026-2015
4. Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73:581-3. doi: 10.1136/thoraxjnl-2016-209701
5. Kim JS, Murray S, Yow E, et al. Comparison of pirfenidone and nintedanib: post hoc analysis of the CleanUP-IPF study. Chest. 2024;165:1163-73. doi: 10.1016/j.chest.2023.11.035
6. Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21:411. doi: 10.1186/s12890-021-01783-1
7. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92. doi: 10.1056/NEJMoa1402582
8. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-9. doi: 10.1016/S0140-6736(11)60405-4
9. Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung. 2016;194:739-43. doi: 10.1007/s00408-016-9912-1
10. Chung MP, Park MS, Oh IJ, et al. Safety and efficacy of pirfenidone in advanced idiopathic pulmonary fibrosis: a nationwide post-marketing surveillance study in Korean patients. Adv Ther. 2020;37:2303-16. doi 10.1007/s12325-020-01328-8
11. Pastre J, Barnett S, Ksovreli I, et al. Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respir Res. 2021;22:5. doi:10.1186/s12931-020-01601-6
12. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60:2101499. doi: 10.1183/13993003.01499-2021
13. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428-46. doi:10.1183/09031936.00150314
14. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684-91. doi: 10.7326/0003-4819-156-10-201205150-00004
15. Kazerooni EA, Austin JH, Black WC, et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4). J Thorac Imaging. 2014;29:310-6. doi: 10.1097/RTI.0000000000000097
16. Oda K, Ishimoto H, Yatera K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:10. doi:10.1186/1465-9921-15-10
17. Chahal A, Sharif R, Watts J, et al. Predicting outcome in idiopathic pulmonary fibrosis: addition of fibrotic score at thin-section CT of the chest to gender, age, and physiology score improves the prediction model. Radiol Cardiothorac Imaging. 2019;1:e180029. doi:10.1148/ryct.2019180029
18. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340-6. doi: 10.1136/thoraxjnl-2016-208710
19. Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48:843-51. doi: 10.1183/13993003.01966-2015
20. Behr J, Nathan SD, Costabel U, et al. Efficacy and safety of pirfenidone in advanced versus non-advanced idiopathic pulmonary fibrosis: post-hoc analysis of six clinical studies. Adv Ther. 2023;40:3937-55. doi: 10.1007/s12325-023-02565-3.
21. Man RK, Gogikar A, Nanda A, et al. A comparison of the effectiveness of nintedanib and pirfenidone in treating idiopathic pulmonary fibrosis: a systematic review. Cureus. 2024;16:e54268. doi: 10.7759/cureus.54268
22. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
